Hementin
Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.
- Hementin80 kDa
- Hementerin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- LHyal (Leech Hyaluronidase)50 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Hementin's in vitro fibrinogenolytic activity does not establish clinical efficacy as a thrombolytic. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.
Molecular Profile
- Category
- Fibrinolytic
- Evidence tier
- Preclinical
- Molecular weight
- 80,000 Da
- Source species
- Haementeria ghilianii (giant Amazon leech)
- Discovered
- 1984 · Malinconico, Budzynski et al.
Biological Targets
- → fibrinogen Aα and Bβ chains
Key Citations
- Malinconico SM et al. (1984), Thromb Res · PMID 6387015
External Resources
Related Fibrinolytic Compounds
Destabilase
Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.
Hementerin
Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.
Destabilase Isopeptidase Activity
Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.
Destabilase-2
Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.